Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has issued a notice to Ligand Pharmaceutical declaring its termination of collaboration and licensing agreement on developing hepatitis C treatment between Roche and a unit of Ligand Pharma, Metabasis Therapeutics.
Subscribe to our email newsletter
Executed in August 2008, the agreement allows Roche to develop hepatitis C viral (HCV) compounds while using Metabasis’ liver-targeting technology.
Earlier, in April Roche has paid $6.5m payment to Ligand Pharma following Roche’s initiation of RG7348 Phase I clinical trial.
As per the collaboration and licensing agreement Roche’s termination is expected to be in effect after 60 days prior written notice.
Following the termination of the deal, Roche will not be able to get into any development and commercialisation agreement on the related compounds.